Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date: February 10, 2026
Subject: Announcement of results from the 36-week blinded maintenance period of the Phase 2b REZOLVE-AD study for rezpegaldesleukin, a regulatory T-cell biologic for moderate-to-severe atopic dermatitis (AD).
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial results and regulatory updates. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
The filing details significant clinical progress for rezpegaldesleukin in the REZOLVE-AD study (N=393 patients). Key outcomes from the 36-week maintenance period include:
- Sustained Efficacy: Q4W (every 4 weeks) and Q12W (every 12 weeks) dosing regimens demonstrated sustained disease control for EASI-75, EASI-90, vIGA-AD, and Itch NRS responses.
- High Maintenance Rates: Among re-randomized patients achieving EASI-50 in induction, the 24 µg/kg Q12W regimen maintained EASI-75 response in 83% of patients and EASI-90 in 78%.
- New Responses: A meaningful proportion of patients achieved new high-level responses (EASI-75, EASI-90, vIGA-AD 0/1) at Week 52.
- EASI-100 Improvement: A 2 to 5-fold increase in EASI-100 response was observed in maintenance. Specifically, 24 µg/kg Q4W dosing increased EASI-100 response from 4% to 22%, and Q12W dosing increased it from 9% to 18% among all re-randomized patients.
- Safety Profile: The drug was well-tolerated with no new safety concerns. The discontinuation rate due to adverse events was 3.5%. Injection site reactions were the most frequent adverse event, with 77% being mild.
Guidance, Outlook, and Regulatory Status
FDA Alignment: The Company held an End of Phase 2 meeting with the FDA and reached alignment on the design for two planned Phase 3 registrational trials.
- Proposed Phase 3 Design: 24 µg/kg Q2W (every 2 weeks) dose regimen for a 24-week induction period with co-primary endpoints of EASI-75 and an IGA-related endpoint.
- Maintenance Evaluation: Phase 3 trials will include a 36-week maintenance period evaluating 24 µg/kg Q4W and 24 µg/kg Q12W regimens.
- Target Population: Expected to include biologic-naive patients and potentially biologic-experienced patients (prior biologics or JAK inhibitors).
- Timeline: The Company plans to start Phase 3 trials in the second quarter of 2026.
Risks: The filing includes standard forward-looking statement disclaimers regarding the risks of clinical development, regulatory approval, and potential delays in trial commencement or data availability.
Investor Verification Checklist
- Verify the specific statistical significance of the EASI-100 improvements in the maintenance period.
- Confirm the final patient population criteria for the upcoming Phase 3 trials (biologic-naive vs. experienced).
- Monitor the actual start date of Phase 3 trials against the Q2 2026 guidance.
- Review the full safety data regarding injection site reactions and long-term tolerability in the maintenance period.
- Check for any updates on the Company's cash runway, as this filing does not disclose financial liquidity.